pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 23·1 min read
save

Medicare proposal threatens funding for remote patient monitoring programs

Jul 23, 2026·read at Endpoints ↗RegulatoryNegative

Medicare announced a proposal to sharply reduce reimbursement for remote patient monitoring services, reversing earlier policy support.

The change would cut payments to firms that supply technology allowing doctors to track patients at home, prompting concern among health‑tech companies.

Industry analysts say the move could slow adoption of RPM tools and impact revenue for vendors that depend on Medicare payments.

The proposal is framed as a cost‑control measure, but critics warn it may hinder efforts to manage chronic conditions remotely.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “What’s behind the proposed pullback on remote patient monitoring”

read at Endpoints ↗
82 words · retrieved Jul 23
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Vyome Holdings, Inc

related stories

  • Aug 18Trump is taking credit for lower list prices. But a Biden-era law did a lot of the heavy liftingEndpoints
  • Aug 13'Incorrect and misleading' data prompted decision to pull Tavneos in EuropeEndpoints
  • Jul 20House lawmakers back trade probe of China biotech, sequencingEndpoints
  • Jul 14Former Akero team announces new I&I company, Avere, with China drugEndpoints
  • Jul 8HHS lays groundwork for new FDA rule on releasing CRLsEndpoints